Kameel D. Farag - 22 Oct 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Interim CFO
Signature
/s/ Abizer Gaslightwala, Attorney-in-Fact
Issuer symbol
AKTX
Transactions as of
22 Oct 2025
Net transactions value
+$4,645
Form type
4
Filing time
24 Oct 2025, 09:18:57 UTC
Previous filing
28 Oct 2025
Next filing
04 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Farag Kameel D. Interim CFO C/O AKARI THERAPEUTICS PLC, 401 EAST JACKSON STREET, SUITE 3300, TAMPA /s/ Abizer Gaslightwala, Attorney-in-Fact 24 Oct 2025 0002093620

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKTX American Depositary Shares representing Ordinary Shares Award $4,645 +6,277 $0.7400 6,277 22 Oct 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer
F2 These ADSs represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 2,000 Ordinary Shares par value $0.0001. The RSUs shall vest on October 31, 2025.